Edgewise Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Edgewise Therapeutics, Inc. | EWTX - NASDAQ |
$14.00-$16.00 | $16.00 | $27.00 | 11 million | 3/26/2021 |
| JP Morgan, Goldman Sachs, SVB Leerink | ||||||
Co-Manager(s): Wedbush PacGrow
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-03-05 Terms Added 2021-03-22 | ||||||
Edgewise Therapeutics, Inc. Quote & Chart - Click for current quote - EWTX
IPO Boutique aggregates information on public companies and private companies, such as "EWTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Edgewise Therapeutics, Inc. (adapted from Edgewise Therapeutics, Inc. prospectus):
They aim to build a leading, global biopharmaceutical company focused on rare diseases involving muscle in order to develop transformative precision medicines to treat and possibly cure these (muscle) disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They aim to build a leading, global biopharmaceutical company focused on rare diseases involving muscle in order to develop transformative precision medicines to treat and possibly cure these (muscle) disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "EWTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.